Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action
暂无分享,去创建一个
John Winslow | T. Dao-Pick | K. Strommen | Gordon Parry | L. Goodman | Lisa DeFazio-Eli | Laurie Goodman | Kristi Strommen | Trang Dao-Pick | G. Parry | J. Winslow | Lisa Defazio-Eli
[1] U. Landegren,et al. Flow cytometric in situ proximity ligation analyses of protein interactions and post‐translational modification of the epidermal growth factor receptor family , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[2] J. Harney,et al. Topological Analysis of the Integral Membrane Protein, Type 1 Iodothyronine Deiodinase (D1) (*) , 1995, The Journal of Biological Chemistry.
[3] T. Wohland,et al. Investigation of the dimerization of proteins from the epidermal growth factor receptor family by single wavelength fluorescence cross-correlation spectroscopy. , 2007, Biophysical journal.
[4] I. Madshus,et al. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization , 2009, Molecular Cancer Therapeutics.
[5] Brian Higgins,et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.
[6] J. Baselga,et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] E. Petricoin,et al. Discovery of a new phospho-HER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] T. Isobe,et al. Epiregulin , 1995, The Journal of Biological Chemistry.
[9] C. Benz,et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] C. Arteaga,et al. Unliganded Epidermal Growth Factor Receptor Dimerization Induced by Direct Interaction of Quinazolines with the ATP Binding Site* , 1997, The Journal of Biological Chemistry.
[11] E. Shpall,et al. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] M. Sliwkowski,et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. , 2009, Cancer cell.
[13] S. Bates,et al. Transforming Growth Factor α Production and Epidermal Growth Factor Receptor Expression in Normal and Oncogene Transformed Human Mammary Epithelial Cells , 1989 .
[14] B. Ljung,et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. , 2006, Journal of the National Comprehensive Cancer Network : JNCCN.
[15] M. Sliwkowski,et al. Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor* , 2002, The Journal of Biological Chemistry.
[16] Xianglin Shi,et al. Individualized survival and treatment response predictions for breast cancers using phospho-EGFR, phospho-ER, phospho-HER2/neu, phospho-IGF-IR/In, phospho-MAPK, and phospho-p70S6K proteins. , 2007, The International journal of biological markers.
[17] C. Singer,et al. Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients , 2010, Clinical Cancer Research.
[18] M. Dowsett,et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer , 2010, Breast Cancer Research.
[19] G. Plowman,et al. Structure and function of human amphiregulin: a member of the epidermal growth factor family. , 1989, Science.
[20] M. Sliwkowski,et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. , 2008, Cancer research.
[21] J. Montero,et al. Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. Petropoulos,et al. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance , 2010, Breast Cancer Research and Treatment.
[23] Toshio Yanagida,et al. Single-molecule imaging of EGFR signalling on the surface of living cells , 2000, Nature Cell Biology.
[24] D. Agus,et al. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth , 2005, Cancer.
[25] Carlos L Arteaga,et al. Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network , 2007, Clinical Cancer Research.
[26] L. Presta,et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab , 2006, Cancer Immunology, Immunotherapy.
[27] A. Scott,et al. The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor AG1478 Increases the Formation of Inactive Untethered EGFR Dimers , 2007, Journal of Biological Chemistry.
[28] P. Auclair,et al. Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study , 2009, BMC Cancer.
[29] P. LoRusso,et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] G. Sledge,et al. A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer , 2008, Clinical Cancer Research.
[31] M. Waterfield,et al. Epidermal growth factor binding induces a conformational change in the external domain of its receptor. , 1989, The EMBO journal.
[32] M. Urashima,et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. , 2009, The oncologist.
[33] M. Sliwkowski,et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.
[34] J. Baselga,et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity , 2009, Oncogene.
[35] D. Allred,et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[36] Stephen Williams,et al. Profiling the HER3/PI3K Pathway in Breast Tumors Using Proximity-Directed Assays Identifies Correlations between Protein Complexes and Phosphoproteins , 2011, PloS one.
[37] Yining Shi,et al. A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer Tissue , 2009, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[38] R. Nicholson,et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. , 2001, Endocrine-related cancer.
[39] R. Nicholson,et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. , 2003, Endocrinology.
[40] Caroline Lohrisch,et al. The Predictive Value of HER2 in Breast Cancer , 2001, Oncology.
[41] I. Maruyama,et al. All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells , 2008, Journal of Cell Science.
[42] Krystal J Alligood,et al. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) , 2004, Cancer Research.
[43] C. Petropoulos,et al. Analytical Validation of a Highly Quantitative, Sensitive, Accurate, and Reproducible Assay (HERmark®) for the Measurement of HER2 Total Protein and HER2 Homodimers in FFPE Breast Cancer Tumor Specimens , 2010, Pathology research international.
[44] M. Kuwano,et al. Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs , 2006, Clinical Cancer Research.
[45] D. Hanahan,et al. Betacellulin: a mitogen from pancreatic beta cell tumors. , 1993, Science.
[46] Zhaocai Zhou,et al. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3–p185her2/neu and the EGFR–p185her2/neu complexes , 2008, Oncogene.
[47] H. Phillips,et al. c‐erbb growth‐factor‐receptor proteins in ovarian tumours , 1995, International journal of cancer.
[48] M. Arbushites,et al. HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer , 2008, Clinical Cancer Research.
[49] S. Bates,et al. Transforming growth factor alpha production and epidermal growth factor receptor expression in normal and oncogene transformed human mammary epithelial cells. , 1989, Molecular endocrinology.
[50] A. Thor,et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] R. Cardiff,et al. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice , 1996, Molecular and cellular biology.
[52] A. Laenkholm,et al. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors , 2009, Breast Cancer Research.
[53] C. Heldin,et al. Dimerization of cell surface receptors in signal transduction , 1995, Cell.
[54] R. Cardiff,et al. Active signaling by Neu in transgenic mice , 1998, Oncogene.
[55] M. Klagsbrun,et al. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF , 1991, Science.
[56] J. Schlessinger,et al. Demonstration of epidermal growth factor-induced receptor dimerization in living cells using a chemical covalent cross-linking agent. , 1988, The Journal of biological chemistry.
[57] M. Belvin,et al. Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab , 2009, Clinical Cancer Research.
[58] C. Hudis,et al. Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer , 2005, Cancer investigation.
[59] K. Gibson,et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. , 2002, Cancer research.
[60] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[61] M. Clynes,et al. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[62] I. Fidler,et al. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. , 2008, Neoplasia.
[63] Aaron S. Gajadhar,et al. A proximity ligation assay using transiently transfected, epitope-tagged proteins: application for in situ detection of dimerized receptor tyrosine kinases. , 2010, BioTechniques.
[64] Y. Yarden,et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.
[65] K. Kawahara,et al. Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. , 2008, Human pathology.
[66] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[67] E. Mekada,et al. Ligand-independent dimer formation of epidermal growth factor receptor (EGFR) is a step separable from ligand-induced EGFR signaling. , 2002, Molecular biology of the cell.
[68] C R King,et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.
[69] C. James,et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[70] Lihua Shao,et al. Erlotinib directly inhibits HER2 kinase activation and downstream signaling events in intact cells lacking epidermal growth factor receptor expression. , 2007, Cancer research.
[71] C. Hudis. Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.
[72] I. Ellis,et al. Epidermal growth factor receptor expression in breast cancer: Association with response to endocrine therapy , 2004, Breast Cancer Research and Treatment.
[73] E. Wight,et al. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. , 2006, European journal of cancer.